# A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S

> **NCT02252640** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Oxford** · enrollment: 48 (actual)

## Conditions studied

- Plasmodium Falciparum Malaria

## Interventions

- **BIOLOGICAL:** RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)
- **BIOLOGICAL:** RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)
- **BIOLOGICAL:** ChAd63 ME-TRAP (5 x 10^10 vp)
- **BIOLOGICAL:** MVA ME-TRAP (2 x 10^8 pfu)

## Key facts

- **NCT ID:** NCT02252640
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2015-12-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02252640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02252640, "A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02252640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*